NIH resumes grant reviews after two-week pause

The changes signal a relaxing of certain Trump administration restrictions at health agencies.

February 4, 2025 Check out STAT+

Sponsored By

For World Cancer Day, get 50% off your first year of STAT+ and stay up to date on the latest trends and groundbreaking discoveries in research.

David Dermer/AP He ruled the operating room and then daytime TV. Now, Dr. Oz is set to take over a $1.5 trillion health agency Sometimes dismissed as a "quack grifter" or "health care huckster," the surgeon turned daytime TV host has a large contingent of loyal supporters. By Tara Bannow Senate Republicans advance RFK Jr.'s confirmation and warn him on vaccines Kennedy nomination clears major hurdle as GOP senators appear to draw a red line on vaccines and say they'll keep a close eye on RFK Jr. By Lizzy Lawrence STAT+ | NIH resumes grant reviews after two-week pause, along with some communications and travel The changes indicate a relaxing of restrictions on NIH employee travel, procurement, and communications imposed by the Trump administration By Megan Molteni and Anil Oza Adobe Opinion: Former surgeon general: America needs a better discourse on DEI Former Surgeon General Jerome Adams writes that DEI discussions require more nuance, especially when it comes to health care. By Jerome Adams RFK Jr. likely to win confirmation to top Trump health role as key GOP senator says he'll vote yes Sen. Bill Cassidy says RFK Jr. won his support after the HHS nominee made commitments to protect vaccines. By John Wilkerson, Isabella Cueto, Rachel Cohrs Zhang, and Lizzy Lawrence STAT+ | Merck's earnings miss focused attention on Gardasil. The real issue is Keytruda The cancer drug will lose its patent exclusivity in 2028. And it could face lower reimbursement from Medicare under the Inflation Reduction Act before that. By Matthew Herper Adobe Opinion: U.S. taxpayers should stop funding clinical trials of industry-owned drugs The current paradigm of government-funded cancer clinical trials — doing industry's work for it — is not working for taxpayers. By Mark J. Ratain

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser